{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:41:59Z","timestamp":1783132919803,"version":"3.54.6"},"reference-count":59,"publisher":"The Society for Free Radical Research Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Biochem. Nutr."],"published-print":{"date-parts":[[2021,3,1]]},"DOI":"10.3164\/jcbn.20-129","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T22:06:25Z","timestamp":1608933985000},"page":"173-180","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study"],"prefix":"10.3164","volume":"68","author":[{"given":"Hiroshi","family":"Tobita","sequence":"first","affiliation":[{"name":"Division of Hepatology, Shimane University Hospital"},{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomotaka","family":"Yazaki","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Shimane University Hospital"},{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Division of Hepatology, Shimane University Hospital"},{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kotani","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Mishiro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Ishimura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Naora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of International Medicine, Izumo City General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Shimane University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1739","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M.  Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73\u201384.","DOI":"10.1002\/hep.28431"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Eguchi Y, Hyogo H, Ono M, et al.; JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol 2012; 47: 586\u2013595.","DOI":"10.1007\/s00535-012-0533-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413\u20131419.","DOI":"10.1016\/S0016-5085(99)70506-8"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Gastroenterol Hepatol 2009; 7: 234\u2013238.","DOI":"10.1016\/j.cgh.2008.11.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389\u2013397.","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Ekstedt M, Hagstr\u00f6m H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547\u20131554.","DOI":"10.1002\/hep.27368"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Seko Y, Sumida Y, Tanaka S, et al. Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 2014; 45: E53\u2013E61.","DOI":"10.1111\/hepr.12456"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015; 149: 367\u2013378.e5.","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Sberna AL, Bouillet B, Rouland A, et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabet Med 2018; 35: 368\u2013375.","DOI":"10.1111\/dme.13565"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD\/NASH. J Gastroenterol 2018; 53: 362\u2013376.","DOI":"10.1007\/s00535-017-1415-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335\u20131343.","DOI":"10.2337\/dc07-0228"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Iwasaki T, Yoneda M, Inamori M, et al. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103\u20132105.","DOI":"10.5754\/hge11263"},{"key":"13","unstructured":"13 Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75: 240\u2013244."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Arase Y, Kawamura Y, Seko Y, et al. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res 2013; 43: 1163\u20131168.","DOI":"10.1111\/hepr.12077"},{"key":"15","unstructured":"15 Fukuhara T, Hyogo H, Ochi H, et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014; 61: 323\u2013328."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Cui J, Philo L, Nguyen P, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016; 65: 369\u2013376.","DOI":"10.1016\/j.jhep.2016.04.021"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Joy TR, McKenzie CA, Tirona RG, et al. Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized, placebo-controlled trial. World J Gastroenterol 2017; 23: 141\u2013150.","DOI":"10.3748\/wjg.v23.i1.141"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Hussain M, Majeed Babar MZ, Hussain MS, Akhtar L. Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease. Pak J Med Sci 2016; 32: 1396\u20131401.","DOI":"10.12669\/pjms.326.11133"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014; 5: 355\u2013366.","DOI":"10.1007\/s13300-014-0089-4"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia 2018; 61: 1923\u20131934.","DOI":"10.1007\/s00125-018-4675-2"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care 2018; 41: 1801\u20131808.","DOI":"10.2337\/dc18-0165"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res Clin Exp 2017; 87: 13\u201319.","DOI":"10.1016\/j.curtheres.2017.07.002"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Inoue M, Hayashi A, Taguchi T, et al. Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig 2019; 10: 1004\u20131011.","DOI":"10.1111\/jdi.12980"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Pract 2018; 4: 477\u2013482.","DOI":"10.1002\/osp4.294"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ito D, Shimizu S, Inoue K, et al. Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial. Diabetes Care 2017; 40: 1364\u20131372.","DOI":"10.2337\/dc17-0518"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Shibuya T, Fushimi N, Kawai M, et al. Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. Diabetes Obes Metab 2018; 20: 438\u2013442.","DOI":"10.1111\/dom.13061"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Miyake T, Yoshida S, Furukawa S, et al. Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease. Open Med (Wars) 2018; 13: 402\u2013409.","DOI":"10.1515\/med-2018-0059"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Tabuchi H, Maegawa H, Tobe K, Nakamura I, Uno S. Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results). Endocr J 2019; 66: 31\u201341.","DOI":"10.1507\/endocrj.EJ18-0217"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, as a second-line treatment for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors. Clin Drug Investig 2016; 36: 313\u2013319.","DOI":"10.1007\/s40261-016-0383-1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Sumida Y, Murotani K, Saito M, et al. Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial). Hepatol Res 2019; 49: 64\u201371.","DOI":"10.1111\/hepr.13236"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Kusunoki M, Natsume Y, Sato D, et al. Luseogliflozin, a sodium glucose co-transporter 2 inhibitor, alleviates hepatic impairment in Japanese patients with type 2 diabetes. Drug Res (Stuttg) 2016; 66: 603\u2013606.","DOI":"10.1055\/s-0042-111515"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007; 102: 2708\u20132715.","DOI":"10.1111\/j.1572-0241.2007.01526.x"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539\u2013553.","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Alberti KG, Eckel RH, Grundy SM, et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640\u20131645.","DOI":"10.1161\/CIRCULATIONAHA.109.192644"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Honda T, Chen S, Yonemoto K, et al. Sedentary bout durations and metabolic syndrome among working adults: a prospective cohort study. BMC Public Health 2016; 16: 888.","DOI":"10.1186\/s12889-016-3570-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Mizuno N, Seko Y, Kataoka S, et al. Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease. J Gastroenterol 2019; 54: 160\u2013170.","DOI":"10.1007\/s00535-018-1485-8"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487\u20131495.","DOI":"10.2337\/diacare.27.6.1487"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265\u20131269.","DOI":"10.1136\/gut.2010.216077"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Bailey T, Bode BW, Christiansen MP, Klaff LJ, Alva S. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther 2015; 17: 787\u2013794.","DOI":"10.1089\/dia.2014.0378"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011; 31: 730\u2013739.","DOI":"10.1111\/j.1478-3231.2011.02488.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Kowdley KV, Belt P, Wilson LA, et al.; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012; 55: 77\u201385.","DOI":"10.1002\/hep.24706"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Angulo P, George J, Day CP, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 1163\u20131169.e1.","DOI":"10.1016\/j.cgh.2013.11.035"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Yoneda M, Thomas E, Sumida Y, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: proceed with caution. Hepatol Res 2014; 44: E499\u2013E502.","DOI":"10.1111\/hepr.12327"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Buzzetti E, Petta S, Manuguerra R, et al. Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. Liver Int 2019; 39: 1325\u20131334.","DOI":"10.1111\/liv.14096"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol 2003; 39: 756\u2013764.","DOI":"10.1016\/S0168-8278(03)00376-3"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Mashitani T, Noguchi R, Okura Y, et al. Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes. Biomed Rep 2016; 4: 183\u2013187.","DOI":"10.3892\/br.2016.569"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Adams LA, Crawford DH, Stuart K, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: a prospective, randomized, controlled trial. Hepatology 2015; 61: 1555\u20131564.","DOI":"10.1002\/hep.27662"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Zhou Y, Wei F, Fan Y. High serum uric acid and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Biochem 2016; 49: 636\u2013642.","DOI":"10.1016\/j.clinbiochem.2015.12.010"},{"key":"49","unstructured":"49 Darmawan G, Hamijoyo L, Hasan I. Association between serum uric acid and non-alcoholic fatty liver disease: a meta-analysis. Acta Med Indones 2017; 49: 136\u2013147."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Wu AH, Gladden JD, Ahmed M, Ahmed A, Filippatos G. Relation of serum uric acid to cardiovascular disease. Int J Cardiol 2016; 213: 4\u20137.","DOI":"10.1016\/j.ijcard.2015.08.110"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Wang J, Yu Y, Li X, et al. Serum uric acid levels and decreased estimated glomerular filtration rate in patients with type 2 diabetes: a cohort study and meta-analysis. Diabetes Metab Res Rev 2018; 34: e3046.","DOI":"10.1002\/dmrr.3046"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014; 35: 391\u2013404.","DOI":"10.1002\/bdd.1909"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Omolekulo TE, Michael OS, Olatunji LA. Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid. Biomed Pharmacother 2019; 110: 869\u2013877.","DOI":"10.1016\/j.biopha.2018.12.036"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313\u2013326.","DOI":"10.1016\/j.metabol.2010.09.003"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA.  Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 2002; 87: 4652\u20134656.","DOI":"10.1210\/jc.2002-020694"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Cernea S, Roiban AL, Both E, Hu\u0163anu A. Serum leptin and leptin resistance correlations with NAFLD in patients with type 2 diabetes. Diabetes Metab Res Rev 2018; 34: e3050.","DOI":"10.1002\/dmrr.3050"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Wu P, Wen W, Li J, et al. Systematic review and meta-analysis of randomized controlled trials on the effect of SGLT2 inhibitor on blood leptin and adiponectin level in patients with type 2 diabetes. Horm Metab Res 2019; 51: 487\u2013494.","DOI":"10.1055\/a-0958-2441"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Sano M, Meguro S, Kawai T, Suzuki Y. Increased grip strength with sodium-glucose cotransporter 2. J Diabetes 2016; 8: 736\u2013737.","DOI":"10.1111\/1753-0407.12402"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Okamura T, Hashimoto Y, Osaka T, Fukuda T, Hamaguchi M, Fukui M. The sodium-glucose cotransporter 2 inhibitor luseogliflozin can suppress muscle atrophy in Db\/Db mice by suppressing the expression of <i>foxo1<\/i>. J Clin Biochem Nutr 2019; 65: 23\u201328.","DOI":"10.3164\/jcbn.18-114"}],"container-title":["Journal of Clinical Biochemistry and Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/68\/2\/68_20-129\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T04:00:06Z","timestamp":1615003206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jcbn\/68\/2\/68_20-129\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3164\/jcbn.20-129","relation":{},"ISSN":["0912-0009","1880-5086"],"issn-type":[{"value":"0912-0009","type":"print"},{"value":"1880-5086","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}